Aims/hypothesis. Autoantibodies against CD38 have been found in some patients with Type II (non-insulindependent) diabetes mellitus and have been shown to stimulate insulin secretion by cultured human islets. We tested whether this new form of autoimmunity, (i) overlaps with anti-GAD autoimmunity, (ii) identifies an insulin-deficient phenotype, (iii) is under the influence of genetic factors. Methods. We screened 496 adults by immuno-blot analysis in the Botnia Study (298 with Type II and 98 with Type I (insulin-dependent) diabetes mellitus, 100 non-diabetic control subjects).
pancreas [11, 12, 13] . In rat pancreatic islets, cADPR induces the release of calcium from microsomes [14] . Moreover, in rat and mouse islets (but not in their microsomes) glucose increases the concentration of cADPR; in turn, cADPR stimulates insulin secretion from digitonin-permeabilised islets [14, 15, 16] . Glucose-induced insulin secretion has been shown to be enhanced in transgenic mice overexpressing CD38 in pancreatic beta cells [17] , and attenuated in CD38 knockout mice [18] . Taken together, these observations have led to the hypothesis that CD38 could be involved in insulin secretion through an intracellular calcium mobilisation system alternative to the inositol-3-phosphate pathway [15] .
In recent years, the possibility that an autoimmune reaction against pancreatic beta cells, an event extensively shown in Type I (insulin-dependent) diabetes mellitus, could take place also in some patients with typical Type II (non-insulin-dependent) diabetes mellitus has received increasing attention. Autoantibodies to islet-cell cytoplasmic antigens (ICA), glutamic acid decarboxylase (GAD), and protein tyrosine phosphatase-2 (IA-2) have been detected in subsets of patients with Type II diabetes. The presence of these autoantibodies is associated with a distinct clinical phenotype: autoantibody-positive patients with Type II diabetes are younger, leaner and more insulin deficient than their antibody-negative counterparts [19] .
Recently, the presence of autoantibodies to CD38 has been described both in Japanese [20] and Caucasian [21, 22] patients with Type II diabetes. These findings raise the question of whether Type II diabetic patients with anti-CD38 autoantibodies have a clinical phenotype similar to that of anti-GAD positive patients, who share features of latent autoimmune diabetes (LADA). To answer this question, we screened and characterised a large group of Type II diabetic patients from the Botnia study [23] . Furthermore, we investigated their HLA genotype, as anti-GAD positive patients often show a genotype similar to that of autoimmune Type I diabetes [19] .
Genetic factors also play an important part in the pathogenesis of Type II diabetes. However, the genetic factors are largely unknown except for mutations causing monogenic forms of diabetes, which have been shown in the insulin, insulin receptor, glucokinase and mitochondrial genes together with genes for several transcription factors [24, 25] . Recently, another study [26] that screened for mutations in the CD38 gene, reported a missense mutation causing an aminoacid substitution -Arg140Trp -in exon 3 in 4 out of 31 Type II diabetic Japanese patients but in none of the control subjects. Furthermore, a different study [27] reported a bi-allelic restriction-fragment length polymorphism (RFLP) in intron 1 for the enzyme PvUII in Italian patients. In that study, only three AA homozygous patients were found and two of them had Type II diabetes. The aims of this study therefore were to evaluate the prevalence of CD38ab and of CD38 gene mutations and polymorphisms in Type I and II diabetic patients.
Subjects and methods
Subjects. From the database of the Botnia Study, which is a cohort-based study of Type II diabetes [23] , we selected 298 Caucasian patients with Type II diabetes according to the revised World Health Organisation (WHO) criteria [28, 29] , and 100 non-diabetic subjects with no family history of diabetes and normal fasting plasma glucose concentrations (<6.1 mmol/l) ( Table 1) . By selection, the diabetic group included 100 anti-GAD positive patients and 198 anti-GAD negative patients who were representative of the whole Botnia diabetic cohort with respect to BMI and age at diagnosis of diabetes. Blood samples were obtained after an overnight fast and stored at -20°C until use. In 283 subjects (187 patients and 96 control subjects), an OGTT (75 g) was carried out, with blood sampling at 0, 30, 60 and 120 min after glucose ingestion.
We also studied 98 patients (55 men, 43 women) with Type I diabetes (with a mean fasting C-peptide concentration of 0.02±0.06 nmol/l) extracted from the Diabetes 2000 Registry in Southern Sweden (Table 1 ) . Informed consent was obtained from all study subjects; the protocol was approved by the local Ethics Committee.
Detection of anti-CD38 antibodies.
To screen for the presence of anti-CD38 autoantibodies, immunoblotting was carried out using a recombinant CD38-maltose binding protein (MBP) fusion protein of 68 kilo-Dalton obtained, as previously described, from a human CD38 cDNA encoding amino acids 45-300 [30] . Of recombinant CD38-MBP, 20 µg were electrophoresed on 10% SDS polyacrylamide gel and electrotransferred to polyvinylidene fluoride membrane (PVDF, Immobilon P, Millipore, Bedford, Mass., USA). After preincubation of the membrane with phosphate buffered saline (PBS) containing 5% non-fat dry milk and 0.15% Tween 20 (blocking solution) for 60 min, the sera were diluted 1:1000 in the same buffer and incubated with the membrane for 60 min using a Screener Blotter Mini 56 (Samplatec, Osaka, Japan). The membranes were washed with PBS-Tween and incubated for 60 min with a rabbit anti-human antibody labelled with horseradish peroxidase (American Quialex, La Mirada, Calif., USA) diluted 1:1600. The signals were revealed using an enhanced chemiluminescence detection system (ECL, Amersham, Arlington, Ill., USA), and quantitated by densitometry. The images were acquired using a Hamamatsu CCD C3077/-01 videocamera (Hamamatsu Photonics KK, Japan) connected to an IQ Base software (Hamamatsu Photonics KK), and analysed using the Image 1.28 software (W. Rasband, National Institute of Health, Research Service Branch, NIMH, Bethesda, Md., USA). The specificity of the signals was assessed by the following tests: (i) Three diabetic sera positive for anti-CD38 antibodies were incubated overnight at 4°C with or without 100 µg/ml of human recombinant CD38-MBP or LacZ-MBP in blocking solution [20, 21] , and used for immunoblotting. (ii) Six anti-CD38 positive and six anti-CD38 negative diabetic sera diluted 1:1,000 were immunoblotted against the extracellular domain of human CD38, with the putative glycosylation sites eliminated by site-directed mutagenesis, obtained by recombinant expression technique from the yeast, Pichia pastoris (1 µg/lane) [31] . (iii) Signals obtained from diabetic or normal sera were compared with those produced by an anti-human-CD38 monoclonal antibody (T16, Cosmo Bio Co., Tokyo, Japan) tested on the same PVDF membrane at the concentration of 5 µg/ml. (iv) Serum samples positive for the presence of anti-CD38 antibodies were immunoblotted with a recombinant LacZ-MBP fusion protein to exclude the presence of antibodies directed against MBP. The inter-assay variation coefficient of anti-CD38 autoantibodies by immunoblotting was 8%.
Analytical measurements. Plasma glucose concentrations were measured with a hexokinase method (Boehringer Mannheim, Mannheim, Germany). Serum insulin concentrations were measured by radioimmunoassay (Pharmacia, Uppsala, Sweden) with an inter-assay CV of 5%. Fasting serum C-peptide concentrations were measured by a radioimmunoassay with an inter-assay CV of 9% (Human C-peptide RIA Kit, Linco Research, Mo., USA). HbA 1c concentration was measured by a high-performance liquid chromatography, with a reference value of 5 to 7%. The plasma concentrations of cholesterol and triglycerides and separate lipoprotein fractions were measured by enzymatic methods using commercial kits (Boehringer Mannheim, Mannheim, Germany). GAD autoantibodies (GADab) were measured from frozen serum samples by a radioimmunoprecipitation assay using recombinant human 35 S-GAD 65 produced by in vitro transcription/translation [19] . The results were expressed as relative units [RU = (sample cpm-mean cpm of three negative controls)/(cpm of a positive internal references serum-mean cpm of three negative controls)]. Antibody concentrations exceeding 5 RU, which represents the mean + 3 SD of 296 Finnish healthy control subjects, were considered positive. In the Combined Autoantibody Workshop, the specificity of the assay was 99% and the sensitivity was 75% [32] . A GADab level of 5 RU in our study corresponds to 32 IU/ml according to the WHO standard [33] .
HLA DQB1 genotypes. HLA DQB1 genotyping was carried out by polymerase chain reaction (PCR) for the second exon followed by dot-blot hybridisation with sequence-specific oligonucleotide (SSO) probes labelled with digoxigenin (DIG Oligonucleotide 3′-End Labelling Kit, Boehringer Mannheim, Mannheim, Germany) [19] . Three DQB1 probes were used to ation at 94°C, for 60 s, annealing between 56 to 62°C, for 60 s and extension at 72°C, for 45 s followed by a final extension of 10 min at 72 °C. After denaturation with 3 µl of a stop solution (95% formaldehyde, 20 mmol/l EDTA, 0.05% bromophenol blue and 0.05% xylene cyanol) at 95°C for 5 min, 6 µl of each amplicon was electrophoresed on non-denaturing 5% polyacrylamide (Acrylamide/Bisacrylamide 49:1) gels with 5% glycerol at room temperature (8 Watt overnight), and without glycerol at 4°C (35 Watt for 4 h). Following electrophoresis, gels were dried in a gel dryer and then exposed on X-rays films overnight.
Genotyping the known single nucleotide polymorphisms in intron 1 and exon 3. We typed two published polymorphisms in all Type II diabetic and control subjects (n=398). The C→T polymorphism at codon 140 of exon 3 (Arg140Trp) was typed according to another study [26] . Briefly, 12 µl of the PCR fragments were digested at 65°C for 3 h with 0. 
Results

Detection of anti-CD38 antibodies in human serum.
A band of about 68 kilo-Dalton was observed in the sera of some diabetic patients and normal subjects. The autoradiografic signals were abolished by preincubating anti-CD38 positive sera with recombinant CD38 but not with LacZ-MBP [21, 22] . When anti-CD38 positive and anti-CD38 negative sera were screened against recombinant CD38 from P. pastoris, a band of approximately 30 kilo-Dalton, corresponding to the soluble CD38, and a higher molecular mass species (probably due to self-aggregation) were observed for all six anti-CD38 positive sera, whereas no signal was detected with six anti-CD38 negative sera. In the whole study group, the distribution of optical density values of the diabetic group clearly diverged from that of the non-diabetic group above the 90 th percentile (Fig. 1) . In the control subjects, optical density was not related to sex (r 2 =0.005, p=NS), age (r 2 =0.08, p=NS), or BMI (r 2 =0.10, p=NS). By defining anti-CD38 positivity as a standardised optical density value at least 3 SDs above the mean value of the control group (i.e., >2.01 OD), 25 of 298 Type II diabetic patients (8.4%) ( Table 1) were positive for anti-CD38 antibodies compared with 4 out of 100 Type I diabetic patients and none of 100 control subjects (χ 2 =10.3, p<0.006). By selection, the diabetic group was enriched with anti-GAD positive patients (33.4%, Table 1). Positivity for anti-CD38 antibodies was associated with positivity for anti-GAD antibodies: 14% of the GADab positive and 5.6% of the GADab negative Type II diabetic patients had CD38ab (χ 2 =12.6, p=0.0004); the respective antibody titres were not, however, related to one another (p=NS). Anti-CD8 Fig. 1 Distribution of the concentrations of anti-CD38 (OD) and anti-GAD (RU) autoantibodies in 298 patients with Type II diabetes and 100 non-diabetic subjects concentrations were weakly related to the duration of the disease in Type II diabetic patients (r=0.15; p=0.01).
The clinical characteristics of Type II diabetic patients stratified by anti-GAD as well as anti-CD38 positivity is shown (Table 2 ). Anti-GAD positive patients had a definite phenotype, consisting of a younger age and an earlier age of disease onset, higher fasting plasma glucose concentrations, and a better lipid and blood pressure profile as compared with patients who were negative for both antibodies. In contrast, the clinical phenotype of anti-CD38 positive patients was similar to that of antibody-negative patients. When both autoantibodies occurred, the dominant phenotype was imposed by anti-GAD positivity. When this analysis was repeated by pooling Type II and Type I patients together, the results were very similar.
The plasma glucose and insulin responses to oral glucose administration are given (Table 3) for the Type II diabetic patients subgrouped according to anti-GAD and anti-CD38 positivity. The plasma glucose response, as the glucose area, did not differ by either antibody positivity and was higher than in control subjects for all diabetic subgroups. The plasma insulin response, on the other hand, was lower in association with anti-GAD, but not anti-CD38, positivity. Consequently, the insulin-to-glucose area ratio (an empirical index of the glucose sensitivity of the beta cell) was lower in anti-GAD positive patients. Furthermore, this ratio was lower than in non-diabetic subjects in all subgroups except for the patients with sole anti-CD38 positivity.
There was no association between CD38 positivity and the HLA-DQB1 genotypes 0201/0302 or 0302/X, which confer increased risk for Type I diabetes (Table 4). However, apart from the presence of GADab, 52% (13/25) of the CD38ab positive Type II diabetic patients had the HLA-DQB1*02 allele compared with 34% (93/273) of the CD38ab negative patients (p=0.08). All four CD38ab positive Type I diabetic patients had DQB1*02. Thus, in the whole study group, 17 of 29 (59%) CD38ab positive subjects had DQB1*02 compared with 176 of 466 (38%) CD38ab negative subjects (p=0.04). By PCR-SSCP in 44 Type II diabetic patients, no mutations were found in any of the eight exons, the 5′ end of intron 1 or the 5′ and 3′ untranslated regions of the CD38 gene. The missense mutation found by another study [26] in exon 3 was also screened for in all Type II diabetic and control subjects (n=398), and was found in none. The allele frequency of the PvUII genotype was 18.4% for the undigested allele A and 81.6% for the digested allele B. There was no association between the PvUII polymorphism genotypes and either CD38ab positivity or diabetic status among the subjects studied. The genotype frequency (AA-AB-BB) was 1.1%-34.4%-64.5% in control subjects, 3.7%-28.9%-67.4% in GADab negative Type II diabetic patients, and 4.3%-29.8%-66.0% in GADab positive Type II diabetic patients (p=NS). There was no association between the PvUII genotypes and clinical phenotype, except for a slightly higher mean systolic blood pressure in those Type II diabetic patients carrying allele A (AA genotype: 157 mmHg, AB genotype: 149 mmHg) compared with those homozygous for allele B (141 mmHg; p=0.04) .
Discussion
This study provides evidence that high-level autoantibodies reacting with human recombinant CD38 are in the sera of patients with Type II diabetes from the Botnia cohort as well as in patients with Type I diabetes from the Diabetes 2000 Registry in Southern Sweden. Specificity tests confirmed that CD38 is indeed the protein recognised by the native autoantibodies. In Type II diabetic patients, positivity for CD38 antibodies was associated with positivity for anti-GAD antibodies. In the whole study group, positivity for anti-CD38 antibodies was associated with DQB1*02.
The prevalence of anti-CD38 antibodies in this Type II diabetic cohort was 8.4%, which is slightly lower than that observed in Japanese [20] or Italian Type II diabetes patients [21, 22] . Given the relatively large sample size in these studies, this result probably refers to the inter-ethnic variability of autoimmune phenomena. In previous studies [20, 21, 22] , no association was found between CD38ab and GADab positivity, although in the Italian study [21] the serum concentrations of the two autoantibodies were weakly correlated. In our study, the prevalence of CD38ab positivity was higher in GADab positive than GADab negative Type II diabetic patients (14% vs 6%, respectively) but the titres of the two autoantibodies were not related to one another. The association of GADab positivity with the presence of other autoantibodies (against thyroid, adrenal gland, or gastric mucosa) in Type II diabetic patients has been reported in an Italian clinic-based cohort [36] . These associations support the view that LADA is one phenotypic expression of a complex autoimmune polyendocrine syndrome, of which the presence of anti-CD38 and anti-GAD autoimmunity in these series could be regarded as a new manifestation.
By selection, the Type II diabetic group included 100 anti-GAD positive patients and 198 anti-GAD negative patients who were representative of the whole Botnia diabetic cohort with respect to BMI and age at diagnosis. The GADab positive patients had an earlier age of onset, higher fasting plasma glucose concentrations and a more favourable cardiovascular risk factor profile as compared with GADab negative patients, as expected [19] . [21] and in dispersed human islet cells [22] . The question, whether prolonged challenge of beta-cell function by stimulating autoantibodies could precipitate overt hyperglycaemia in pre-diabetic individuals, remains open as information on the natural history of anti-CD38 autoimmunity is not available. The finding, that the anti-CD38 titres were related to the duration of the disease in Type II diabetic patients, could suggest that anti-CD38 autoantibodies are associated with a slower progression of the disease. Positivity for anti-GAD autoantibodies has been linked with DQB1*0302 in patients with Type II diabetes in the Botnia study [19] . In this cohort (combined Type I diabetic and Type II diabetic groups), anti-CD38 positivity was weakly associated with HLA-DQB1*02, a genotype that has been found to be associated with GADab positivity in patients with Type I diabetes [37] .
LADA is a familial disease involving autoimmune beta-cell destruction and slow progression towards insulin deficiency [38] . Associations with high-risk HLA genotypes and autoimmune phenomena (GAD, IA2, ICA) show similarities with Type I diabetes but the phenotypical characteristics of these patients do not allow a clear differentiation from non-autoimmune Type II diabetes without screening of anti-GAD autoantibodies [39] . Early identification of LADA patients could be of clinical importance to prevent or delay beta-cell loss by immune intervention. In contrast, the identification of anti-CD38 autoimmunity might indicate a relative protection against beta-cell failure and a lower risk of insulin requirement. In anti-GAD positive patients, the presence of anti-CD38 antibodies could be associated with an attenuation of their risk of beta-cell failure.
With regard to genetic factors, another study [26] screened for mutations in the CD38 gene and reported a missense mutation causing an Arg140 to Trp aminoacid substitution in exon 3 in 4 of 31 Japanese Type II diabetic subjects who had first-degree and/or seconddegree relatives with Type II diabetes (but in none of the 90 Japanese control subjects). CD38 enzyme activity studies using COS-7 cells expressing the Arg140Trp mutation showed reductions in ADP-ribosyl cyclase and cADPR hydrolase activities of about 50%. It was therefore hypothesised that the Arg140Trp mutation could contribute to the development of Type II diabetes via an impairment of glucose-induced insulin secretion. In the same study, a silent polymorphism was found in exon 2 in the codon for Ile168 from ATA to ATC in 16% of Type II diabetic patients and control subjects. In our study, none of the 298 subjects carried the Arg140Trp mutation; likewise, we were not able to find any SSCP variants in exon 2. Therefore, in our cohort the Arg140Trp mutation does not seem to contribute to the development of Type II diabetes either through the impairment of glucose-induced insulin secretion or by inducing the appearance of anti-CD38 autoantibodies.
Regarding the bi-allelic RFLP in intron 1 for the enzyme PvUII, the observed allele frequency in the whole study cohort was 18.4% for allele A and 81.6% for allele B, similar to those reported in healthy Italian subjects (14% vs 86% [27] ). In that study, only three AA homozygous subjects were found and two of them had Type II diabetes. However, no association between Type II diabetes and the PvUII polymorphism was seen in our study.
In conclusion, our study confirms the occurrence of anti-CD38 autoimmunity in both Type II and Type I diabetes in a previously well characterised ethnic group. Despite some degree of association between anti-CD38 and anti-GAD autoimmunity, the clinical phenotypes identified by the two markers were distinct, particularly with regard to in vivo beta-cell function. Other than an association with DQB1*02, no other genetic association was found when extensively exploring the CD38 gene or analysing the PvUII polymorphism.
